French prosecutors probe Sanofi over possible market manipulation -source
Reuters
Published Nov 07, 2023 10:35
Updated Nov 07, 2023 11:03
PARIS (Reuters) -French financial prosecutors have opened a preliminary probe into drugmaker Sanofi (EPA:SASY) over possible share price manipulation, a person close to the investigation said on Tuesday, while the company said it was unaware of any criminal investigation into its past financial reporting.
The person close to the investigation confirmed earlier reports from French media La Lettre and news agency AFP, which said a preliminary probe was opened in March and was linked to possible market manipulation caused by the group's past financial communication.
La Lettre reported the investigation was linked to Sanofi's communication around the launch of its blockbuster drug Dupixent in 2017.
"As a listed company, the financial informations published by Sanofi are accurate, precise and sincere, and are duly audited by two auditing firms," Sanofi said in an emailed statement.
It said it was "not aware of any preliminary investigation by the Parquet National Financier on its 2017 accounts or of any other investigation", adding it reserved the right to take legal action against any false or defamatory allegations.
Sanofi shares were down by as much as 2% midday on Tuesday.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.